Alzheimer’s drug aducanumab sparks emotional battle as FDA nears deadline on whether or not to approve

However the intravenous therapy doesn’t treatment Alzheimer’s or reverse it. It might carry a price ticket as excessive as $50,000-a-year per affected person, based on drug analysts, including billions of {dollars} to the nation’s well being tab. And, relying on how the FDA writes the label, tens of millions of individuals may very well be eligible for the drug, or not less than for an evaluation of whether or not they need to take it, consultants say.

Source link